{
    "clinical_study": {
        "@rank": "85691", 
        "arm_group": [
            {
                "arm_group_label": "Sildenafil", 
                "arm_group_type": "Experimental", 
                "description": "12 patients will be in this group. They will take a sildenafil 50mg."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "12 patients will be in this group, they will take placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac\n      magnetic resonance for ventricular analyses and after this first exam they will be\n      randomized to placebo or Sildenafil. After one hour drug intake they will undergo another\n      cardiac magnetic resonance to evaluate the drug impact on right and left ventricular\n      function."
        }, 
        "brief_title": "Sildenafil Impact on Ventricular Function in Patients With Heart Failure", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac\n      magnetic resonance for ventricular analyses and after this first exam they will be\n      randomized to placebo or sildenafil. After one hour drug intake they will undergo another\n      cardiac magnetic resonance to evaluate the drug impact on right and left ventricular\n      function.\n\n      The first and second exams will be performed by the same staff. All patients will be\n      evaluated by two, three and four chambers view. Left and right ventricle quantification\n      analyses will be performed by Argus software."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Patients with heart failure in stable clinical condition compatible\n        with New York Heart Association functional class I to III. Eligibility criteria is consent\n        to participate in the study after receiving detailed information about procedures,\n        possible clinical benefits, and risks.\n\n        Exclusion Criteria: patients with new diagnosed lesions during the procedure, eg pulmonary\n        mass and important claustrophobia, low blood pressure ( systolic blood pressure <90 mmHg\n        or diastolic blood pressure <60 mmHg) nitrate or nebivolol use over the last 48 hours,\n        metallic non MRI compatible implantable devices."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936350", 
            "org_study_id": "05378712.0.0000.0045"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sildenafil", 
                "description": "The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.", 
                "intervention_name": "Sildenafil", 
                "intervention_type": "Drug", 
                "other_name": "Sildenafil"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo group"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Heart failure", 
        "lastchanged_date": "November 6, 2013", 
        "link": {
            "description": "approved by local Institutional Review Board", 
            "url": "http://aplicacao.saude.gov.br/plataformabrasil/visao/pesquisador/gerirPesquisa/gerirPesquisa.jsf"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Salvador", 
                    "country": "Brazil", 
                    "state": "Bahia", 
                    "zip": "40000"
                }, 
                "name": "Hospital Ana Neri - MRI unit"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sildenafil Impact on Ventricular Function in Patients With Heart Failure: Randomized Clinical Trial", 
        "overall_official": {
            "affiliation": "Hospital Ana Nery - Federal University of Bahia", 
            "last_name": "Andre M Fernandes, Master", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Brazil: Ethics Committee", 
                "Brazil: Ministry of Health", 
                "Brazil: National Committee of Ethics in Research"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients will undergo a cardiac magnetic resonance to evaluate ventricular function after one hour of sildenafil or placebo use", 
            "measure": "Improvement on ventricular function", 
            "safety_issue": "No", 
            "time_frame": "one hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936350"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Ana Nery", 
            "investigator_full_name": "Andre Duraes, PhD", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Hospital Ana Nery", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Ana Nery", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}